Evidence map›Paper›PMID 25502501›Full record

Trial reportAmerican journal of physiology. Lung cellular and molecular physiology2015

Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis.

Fei Liu, David Lagares, Kyoung Moo Choi, Lauren Stopfer, Aleksandar Marinković, Vladimir Vrbanac, Clemens K Probst, Samantha E Hiemer, Thomas H Sisson, Jeffrey C Horowitz and 6 more

Abstract readClinical Trial
In one paragraph

Trial report in American journal of physiology. Lung cellular and molecular physiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 573 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
573citing papers in PubMed, 1 pooled it
14.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

573 citing papers in PubMed, 1 synthesis or guideline pooled it, 785 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. ADAMTS14 is a novel modulator of fibroblast mechanoactivation in pulmonary fibrosis.American journal of respiratory and critical care medicine · 2026
    Article
  9. Article
  10. Review
  11. Collagen Prolyl 4-Hydroxylase: An Emerging Key Player in Cardiac Fibrosis.Journal of cardiovascular translational research · 2026
    Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. A practical toolbox for modelling fibrosis in vitro.Nature biomedical engineering · 2026
    Review
  20. Review

513 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Fei LiuMolecular and Integrative Physiological Sciences, Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts;
David LagaresPulmonary and Critical Care Unit and Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Charlestown, Massachusetts;
Kyoung Moo ChoiDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota;
Lauren StopferDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota;
Aleksandar MarinkovićMolecular and Integrative Physiological Sciences, Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts;
Vladimir VrbanacPulmonary and Critical Care Unit and Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Charlestown, Massachusetts;
Clemens K ProbstPulmonary and Critical Care Unit and Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Charlestown, Massachusetts;
Samantha E HiemerDepartment of Biochemistry, Boston University School of Medicine, Boston, Massachusetts;
Thomas H SissonDivision of Pulmonary and Critical Care Medicine, Department of Medicine, University of Michigan Medical Center, Ann Arbor, Michigan;
Jeffrey C HorowitzDivision of Pulmonary and Critical Care Medicine, Department of Medicine, University of Michigan Medical Center, Ann Arbor, Michigan;
Ivan O RosasDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts;
Laura E FredenburghDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts;
Carol Feghali-BostwickDivision of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina.
Xaralabos VarelasDepartment of Biochemistry, Boston University School of Medicine, Boston, Massachusetts;
Andrew M TagerPulmonary and Critical Care Unit and Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Charlestown, Massachusetts;
Daniel J TschumperlinMolecular and Integrative Physiological Sciences, Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota; tschumperlin.daniel@mayo.edu.
Massachusetts General Hospital · USMayo Clinic · USBoston University · USBrigham and Women's Hospital · USUniversity of Michigan–Ann Arbor · USMedical University of South Carolina · US

Funding

Transgenic CoreP30DK046200 · NIDDK · TUFTS MEDICAL CENTER · PI HU, FRANK B · 1992 to 2021
$25.0M
Mechanobiology of Lung FibrosisR01HL092961 · NHLBI · MAYO CLINIC ROCHESTER · PI Daniel J. Tschumperlin · 2009 to 2026
$8.0M
Translational Research in Regenerative MedicineT32EB005583 · NIBIB · RUTGERS, THE STATE UNIV OF N.J. · PI LEE, KIBUM, PAREKKADAN, BIJU · 2006 to 2022
$4.7M
Defining epithelial polarity cues that direct cell fateR01HL124392 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI VARELAS, XARALABOS · 2014 to 2024
$4.5M
The Anti-protease and Vitronectin-binding Functions of PAI-1 in Lung FibrosisR01HL078871 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SISSON, THOMAS H · 2007 to 2018
$4.0M
Mechanobiology of Vascular Remodeling in Pulmonary Arterial HypertensionR01HL114839 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI FREDENBURGH, LAURA ELIZABETH · 2012 to 2016
$2.1M
Mesenchymal Cell Fate Determination by Extracellular Matrix StiffnessR01HL105489 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HOROWITZ, JEFFREY C · 2011 to 2015
$1.9M
Protective Role of the S1P-S1P1 Pathway in Pulmonary FibrosisR01HL108975 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI TAGER, ANDREW M · 2011 to 2015
$1.8M
The LPA Pathway in Lung Fibrosis: Novel Mediators and New Therapeutic TargetsR01HL095732 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI TAGER, ANDREW M · 2009 to 2010
$922k
Screening Fibroblast-Matrix Stiffness Interactions to ID New Fibrosis TherapiesR21HL113796 · NHLBI · MAYO CLINIC ROCHESTER · PI TSCHUMPERLIN, DANIEL J. · 2013 to 2014
$422k
Arterial Stiffness in the Pathogenesis of Human Pulmonary Arterial HypertensionR03HL115106 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI FREDENBURGH, LAURA ELIZABETH · 2012 to 2013
$174k
NHLBI NIH HHS HL078871NHLBI NIH HHS HL092961NHLBI NIH HHS HL095732NHLBI NIH HHS HL105489NHLBI NIH HHS HL108975NHLBI NIH HHS HL113796NHLBI NIH HHS HL114839NHLBI NIH HHS HL115106NHLBI NIH HHS R01 HL078871NHLBI NIH HHS R01 HL092961NHLBI NIH HHS R01 HL105489NHLBI NIH HHS R01 HL114839NHLBI NIH HHS R01 HL124392NIBIB NIH HHS T32 EB005583NIDDK NIH HHS DK046200NIDDK NIH HHS P30 DK046200
6 · The paper itself

Abstract

Pathological fibrosis is driven by a feedback loop in which the fibrotic extracellular matrix is both a cause and consequence of fibroblast activation. However, the molecular mechanisms underlying this process remain poorly understood. Here we identify yes-associated protein (YAP) (homolog of drosophila Yki) and transcriptional coactivator with PDZ-binding motif (TAZ) (also known as Wwtr1), transcriptional effectors of the Hippo pathway, as key matrix stiffness-regulated coordinators of fibroblast activation and matrix synthesis. YAP and TAZ are prominently expressed in fibrotic but not healthy lung tissue, with particularly pronounced nuclear expression of TAZ in spindle-shaped fibroblastic cells. In culture, both YAP and TAZ accumulate in the nuclei of fibroblasts grown on pathologically stiff matrices but not physiologically compliant matrices. Knockdown of YAP and TAZ together in vitro attenuates key fibroblast functions, including matrix synthesis, contraction, and proliferation, and does so exclusively on pathologically stiff matrices. Profibrotic effects of YAP and TAZ operate, in part, through their transcriptional target plasminogen activator inhibitor-1, which is regulated by matrix stiffness independent of transforming growth factor-β signaling. Immortalized fibroblasts conditionally expressing active YAP or TAZ mutant proteins overcome soft matrix limitations on growth and promote fibrosis when adoptively transferred to the murine lung, demonstrating the ability of fibroblast YAP/TAZ activation to drive a profibrotic response in vivo. Together, these results identify YAP and TAZ as mechanoactivated coordinators of the matrix-driven feedback loop that amplifies and sustains fibrosis.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsCell Cycle ProteinsFemaleFibroblastsGene Knockdown TechniquesHumansIntracellular Signaling Peptides and ProteinsLungMaleMechanotransduction, CellularMiceMice, Inbred NODMutationNIH 3T3 CellsPhosphoproteinsAdaptor Proteins, Signal TransducingCell Cycle ProteinsIntracellular Signaling Peptides and ProteinsPhosphoproteinsPlasminogen Activator Inhibitor 1SERPINE1 protein, humanSerpin E2Serpine2 protein, mouseTrans-ActivatorsTranscriptional Coactivator with PDZ-Binding Motif ProteinsTranscription FactorsTransforming Growth Factor betaWWTR1 protein, humanWwtr1 protein, mouseYAP1 protein, humanYap1 protein, mouseYAP-Signaling Proteinsextracellular matrixHippoidiopathic pulmonary fibrosismechanotransductionplasminogen activator inhibitor 1

Identifiers

PMID25502501
PMCPMC4329470
OpenAlexW2168072233

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.